Abstract
Amphetamine (AMPH) and its derivatives are regularly used in the treatment of a wide array of disorders such as attention-deficit hyperactivity disorder (ADHD), obesity, traumatic brain injury, and narcolepsy (Prog Neurobiol 75:406–433, 2005; J Am Med Assoc 105:2051–2054, 1935; J Am Acad Child Adolesc Psychiatry 41:514–521, 2002; Neuron 43:261–269, 2004; Annu Rev Pharmacol Toxicol 47:681–698, 2007; Drugs Aging 21:67–79, 2004). Despite the important medicinal role for AMPH, it is more widely known for its psychostimulant and addictive properties as a drug of abuse. The primary molecular targets of AMPH are both the vesicular monoamine transporters (VMATs) and plasma membrane monoamine—dopamine (DA), norepinephrine (NE), and serotonin (5-HT)—transporters. The rewarding and addicting properties of AMPH rely on its ability to act as a substrate for these transporters and ultimately increase extracellular levels of monoamines. AMPH achieves this elevation in extracellular levels of neurotransmitter by inducing synaptic vesicle depletion, which increases intracellular monoamine levels, and also by promoting reverse transport (efflux) through plasma membrane monoamine transporters (J Biol Chem 237:2311–2317, 1962; Med Exp Int J Exp Med 6:47–53, 1962; Neuron 19:1271–1283, 1997; J Physiol 144:314–336, 1958; J Neurosci 18:1979–1986, 1998; Science 237:1219–1223, 1987; J Neurosc 15:4102–4108, 1995). This review will focus on two important aspects of AMPH-induced regulation of the plasma membrane monoamine transporters—transporter mediated monoamine efflux and transporter trafficking.
Similar content being viewed by others
References
Sulzer D, Sonders MS, Poulsen NW, Galli A (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75:406–433
Prinzmetal M, Bloomberg W (1935) Use of benzedrine for the treatment of narcolepsy. J Am Med Assoc 105:2051–2054
Olfson M, Marcus SC, Weissman MM, Jensen PS (2002) National trends in the use of psychotropic medications by children. J Am Acad Child Adolesc Psychiatry 41:514–521
Knutson B et al (2004) Amphetamine modulates human incentive processing. Neuron 43:261–269
Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR (2007) New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47:681–698
Martinsson L, Eksborg S (2004) Drugs for stroke recovery: the example of amphetamines. Drugs Aging 21:67–79
Kirshner N (1962) Uptake of catecholamines by a particulate fraction of the adrenal medulla. J Biol Chem 237:2311–2317
Carlsson A, Hillarp NA, Waldeck B (1962) A Mg-ATP dependent storage mechanism in the amine granules of the adrenal medulla. Med Exp Int J Exp Med 6:47–53
Fon EA et al (1997) Vesicular transport regulates monoamine storage and release but is not essential for amphetamine action. Neuron 19:1271–1283
Burn JH, Rand MJ (1958) The action of sympathomimetic amines in animals treated with reserpine. J Physiol 144:314–336
Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci 18:1979–1986
Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 237:1219–1223
Sulzer D et al (1995) Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15:4102–4108
Axelrod J (1965) The metabolism, storage, and release of catecholamines. Recent Prog Horm Res 21:597–622
Jardetzky O (1966) Simple allosteric model for membrane pumps. Nature 211:969–970
Forrest L et al (2008) Mechanism for alternating access in neurotransmitter transporters. Proc Natl Acad Sci USA 105:10338–10343
Erreger K, Grewer C, Javitch JA, Galli A (2008) Currents in response to rapid concentration jumps of amphetamine uncover novel aspects of human dopamine transporter function. J Neurosci 28:976–989
Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA (2008) The mechanism of a neurotransmitter:sodium symporter—inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 30:667–677
Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E (2005) Crystal structure of a bacterial homologue of Na+/Cl-dependent neurotransmitter transporters. Nature 437:215–223
Bruss M, Hammermann R, Brimijoin S, Bonisch H (1995) Antipeptide antibodies confirm the topology of the human norepinephrine transporter. J Biol Chem 270:9197–9201
Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI (1997) Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388:211–227
Chen JG, Liu-Chen S, Rudnick G (1998) Determination of external loop topology in the serotonin transporter by site-directed chemical labeling. J Biol Chem 273:12675–12681
Androutsellis-Theotokis A, Rudnick G (2002) Accessibility and conformational coupling in serotonin transporter predicted internal domains. J Neurosci 22:8370–8378
Granas C, Ferrer J, Loland CJ, Javitch JA, Gether U (2003) N-terminal truncation of the dopamine transporter abolishes phorbol ester- and substance P receptor-stimulated phosphorylation without impairing transporter internalization. J Biol Chem 278:4990–5000
Khoshbouei H et al (2004) N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2:E78
Fog JU et al (2006) Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51:417–429
Li LB et al (2004) The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem 279:21012–21020
Schenk JO (2002) The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate. Prog Drug Res 59:111–131
Seiden LS, Sabol KE, Ricaurte GA (1993) Amphetamine: effects on catecholamine systems and behavior. Annu Rev Pharmacol Toxicol 33:639–677
Raiteri M, Cerrito F, Cervoni AM, Levi G (1979) Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. J Pharmacol Exp Ther 208:195–202
Heikkila RE, Orlansky H, Mytilineou C, Cohen G (1975) Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194:47–56
Parker EM, Cubeddu LX (1988) Comparative effects of amphetamine, phenylethylamine and related drugs on dopamine efflux, dopamine uptake and mazindol binding. J Pharmacol Exp Ther 245:199–210
Fischer JF, Cho AK (1979) Chemical release of dopamine from striatal homogenates: evidence for an exchange diffusion model. J Pharmacol Exp Ther 208:203–209
Burnette WB et al (1996) Human norepinephrine transporter kinetics using rotating disk electrode voltammetry. Anal Chem 68:2932–2938
Zaczek R, Culp S, De Souza EB (1991) Interactions of [3H]amphetamine with rat brain synaptosomes. II. Active transport. J Pharmacol Exp Ther 257:830–835
Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG (1997) Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17:960–974
Sitte HH et al (1998) Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 71:1289–1297
Khoshbouei H, Wang H, Lechleiter JD, Javitch JA, Galli A (2003) Amphetamine-induced dopamine efflux. A voltage-sensitive and intracellular Na+-dependent mechanism. J Biol Chem 278:12070–12077
Pifl C, Singer EA (1999) Ion dependence of carrier-mediated release in dopamine or norepinephrine transporter-transfected cells questions the hypothesis of facilitated exchange diffusion. Mol Pharmacol 56:1047–1054
Pifl C, Rebernik P, Kattinger A, Reither H (2004) Zn(2+) modulates currents generated by the dopamine transporter: parallel effects on amphetamine-induced charge transfer and release. Neuropharmacology 46:223–231
Pifl C, Drobny H, Reither H, Hornykiewicz O, Singer EA (1995) Mechanism of the dopamine-releasing actions of amphetamine and cocaine: plasmalemmal dopamine transporter versus vesicular monoamine transporter. Mol Pharmacol 47:368–373
Pifl C, Agneter E, Drobny H, Reither H, Singer EA (1997) Induction by low Na+ or Cl− of cocaine sensitive carrier-mediated efflux of amines from cells transfected with the cloned human catecholamine transporters. Br J Pharmacol 121:205–212
Seidel S et al (2005) Amphetamines take two to tango: an oligomer-based counter-transport model of neurotransmitter transport explores the amphetamine action. Mol Pharmacol 67:140–151
Kahlig KM et al (2005) Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 102:3495–3500
Melikian HE, Buckley KM (1999) Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19:7699–7710
Carvelli L et al (2002) PI 3-kinase regulation of dopamine uptake. J Neurochem 81:859–869
Loder MK, Melikian HE (2003) The dopamine transporter constitutively internalizes and recycles in a protein kinase C-regulated manner in stably transfected PC12 cell lines. J Biol Chem 278:22168–22174
Giambalvo CT (1992) Protein kinase C and dopamine transport-2. Effects of amphetamine in vitro. Neuropharmacology 31:1211–1222
Kantor L, Gnegy ME (1998) Protein kinase C inhibitors block amphetamine-mediated dopamine release in rat striatal slices. J Pharmacol Exp Ther 284:592–598
Cowell RM, Kantor L, Hewlett GH, Frey KA, Gnegy ME (2000) Dopamine transporter antagonists block phorbol ester-induced dopamine release and dopamine transporter phosphorylation in striatal synaptosomes. Eur J Pharmacol 389:59–65
Kantor L et al (2001) Protein kinase C and intracellular calcium are required for amphetamine-mediated dopamine release via the norepinephrine transporter in undifferentiated PC12 cells. J Pharmacol Exp Ther 297:1016–1024
Kantor L, Zhang M, Guptaroy B, Park YH, Gnegy ME (2004) Repeated amphetamine couples norepinephrine transporter and calcium channel activities in PC12 cells. J Pharmacol Exp Ther 311:1044–1051
Gnegy ME et al (2004) Intracellular Ca2+ regulates amphetamine-induced dopamine efflux and currents mediated by the human dopamine transporter. Mol Pharmacol 66:137–143
Johnson LA, Guptaroy B, Lund D, Shamban S, Gnegy ME (2005) Regulation of amphetamine-stimulated dopamine efflux by protein kinase C beta. J Biol Chem 280:10914–10919
Foster JD, Pananusorn B, Vaughan RA (2002) Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J Biol Chem 277:25178–25186
Kantor L, Hewlett GH, Gnegy ME (1999) Enhanced amphetamine- and K+-mediated dopamine release in rat striatum after repeated amphetamine: differential requirements for Ca2+- and calmodulin-dependent phosphorylation and synaptic vesicles. J Neurosci 19:3801–3808
Pierce RC, Kalivas PW (1997) Repeated cocaine modifies the mechanism by which amphetamine releases dopamine. J Neurosci 17:3254–3261
Binda F et al (2008) Syntaxin1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol 74:1101–1108
Dipace C, Sung U, Binda F, Blakely RD, Galli A (2007) Amphetamine induces a calcium/calmodulin-dependent protein kinase II-dependent reduction in norepinephrine transporter surface expression linked to changes in syntaxin 1A/transporter complexes. Mol Pharmacol 71:230–239
Sung U et al (2003) A regulated interaction of syntaxin 1A with the antidepressant- sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci 23:1697–709
Carvelli L, Blakely RD, DeFelice LJ (2008) Dopamine transporter/syntaxin 1A interactions regulate transporter channel activity and dopaminergic synaptic transmission. Proc Natl Acad Sci USA 105:14192–14197
Fleckenstein AE, Metzger RR, Wilkins DG, Gibb JW, Hanson GR (1997) Rapid and reversible effects of methamphetamine on dopamine transporters. J Pharmacol Exp Ther 282:834–838
Saunders C et al (2000) Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA 97:6850–6855
Kahlig KM, Galli A (2003) Regulation of dopamine transporter function and plasma membrane expression by dopamine, amphetamine, and cocaine. Eur J Pharmacol 479:153–158
Kahlig KM, Javitch JA, Galli A (2004) Amphetamine regulation of dopamine transport. Combined measurements of transporter currents and transporter imaging support the endocytosis of an active carrier. J Biol Chem 279:8966–8975
Kahlig KM et al (2006) Regulation of dopamine transporter trafficking by intracellular amphetamine. Mol Pharmacol 70:542–548
Chi L, Reith ME (2003) Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. J Pharmacol Exp Ther 307:729–736
Gulley JM, Doolen S, Zahniser NR (2002) Brief, repeated exposure to substrates down-regulates dopamine transporter function in Xenopus oocytes in vitro and rat dorsal striatum in vivo. J Neurochem 83:400–411
Owens WA et al (2005) Deficits in dopamine clearance and locomotion in hypoinsulinemic rats unmask novel modulation of dopamine transporters by amphetamine. J Neurochem 94:1402–1410
Williams JM et al (2007) Hypoinsulinemia regulates amphetamine-induced reverse transport of dopamine. PLoS Biol 5:2369–2378
Johnson LA, Furman CA, Zhang M, Guptaroy B, Gnegy ME (2005) Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation. Neuropharmacology 49:750–758
Pristupa ZB et al (1998) Protein kinase-mediated bidirectional trafficking and functional regulation of the human dopamine transporter. Synapse 30:79–87
Daniels GM, Amara SG (1999) Regulated trafficking of the human dopamine transporter. Clathrin-mediated internalization and lysosomal degradation in response to phorbol esters. J Biol Chem 274:35794–35801
Sorkina T, Doolen S, Galperin E, Zahniser NR, Sorkin A (2003) Oligomerization of dopamine transporters visualized in living cells by fluorescence resonance energy transfer microscopy. J Biol Chem 278:28274–28283
Cervinski MA, Foster JD, Vaughan RA (2005) Psychoactive substrates stimulate dopamine transporter phosphorylation and down regulation by cocaine sensitive and protein kinase C dependent mechanisms. J Biol Chem 280:40442–40449
Boudanova E, Navaroli DM, Stevens Z, Melikian HE (2008) Dopamine transporter endocytic determinants: carboxy terminal residues critical for basal and PKC-stimulated internalization. Mol Cell Neurosci 39:211–217
Boudanova E, Navaroli DM, Melikian HE (2008) Amphetamine-induced decreases in dopamine transporter surface expression are protein kinase C-independent. Neuropharmacology 54:605–612
Foster JD, Adkins SD, Lever JR, Vaughan RA (2008) Phorbol ester induced trafficking-independent regulation and enhanced phosphorylation of the dopamine transporter associated with membrane rafts and cholesterol. J Neurochem 105:1683–1699
Wei Y et al (2007) Dopamine transporter activity mediates amphetamine-induced inhibition of Akt through a Ca2+/calmodulin-dependent kinase II-dependent mechanism. Mol Pharmacol 71:835–842
Chu PC, Lin MT, Shian LR, Leu SY (1986) Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 35:481–485
Saitoh A, Morita K, Sodeyama M, Kamei J (1998) Effects of the experimental diabetes on dopamine D1 receptor-mediated locomotor-enhancing activity in mice. Pharmacol Biochem Behav 60:161–166
Karkanias GB, Morales JC, Li CS (1997) Deficits in reproductive behavior in diabetic female rats are due to hypoinsulinemia rather than hyperglycemia. Horm Behav 32:19–29
Doolen S, Zahniser NR (2001) Protein tyrosine kinase inhibitors alter human dopamine transporter activity in Xenopus oocytes. J Pharmacol Exp Ther 296:931–938
Garcia BG et al (2005) Akt is essential for insulin modulation of amphetamine-induced human dopamine transporter cell-surface redistribution. Mol Pharmacol 68:102–109
Galici R et al (2003) Selective decreases in amphetamine self-administration and regulation of dopamine transporter function in diabetic rats. Neuroendocrinology 77:132–140
Lute BJ et al (2008) PI3K signaling supports amphetamine-induced dopamine efflux. Biochem Biophys Res Commun 372:656–661
Zhu MY, Shamburger S, Li J, Ordway GA (2000) Regulation of the human norepinephrine transporter by cocaine and amphetamine. J Pharmacol Exp Ther 295:951–959
Jayanthi LD, Annamalai B, Samuvel DJ, Gether U, Ramamoorthy S (2006) Phosphorylation of the norepinephrine transporter at threonine 258 and serine 259 is linked to protein kinase C-mediated transporter internalization. J Biol Chem 281:23326–23340
Jayanthi LD, Samuvel DJ, Ramamoorthy S (2004) Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. evidence for localization in lipid rafts and lipid raft-mediated internalization. J Biol Chem 279:19315–19326
Mazei-Robison MS et al (2008) Anomalous dopamine release associated with a human dopamine transporter coding variant. J Neurosci 28:7040–7046
Acknowledgements
We thank Dr. Kevin Erreger and Jessica Moore for helpful and insightful discussions. This work was supported by NIH grants MH058921 (Galli, A.), DA13975 (Galli, A.), and MH084755 (Robertson, S.D.).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Robertson, S.D., Matthies, H.J.G. & Galli, A. A Closer Look at Amphetamine-Induced Reverse Transport and Trafficking of the Dopamine and Norepinephrine Transporters. Mol Neurobiol 39, 73–80 (2009). https://doi.org/10.1007/s12035-009-8053-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12035-009-8053-4